Serum metabolomics of end-stage renal disease patients with depression: potential biomarkers for diagnosis

References

• Webster AC, Nagler EV, Morton RL, et al. Chronic kidney disease. Lancet. 2017;389(10075):1238–1252.
   PubMed Web of Science ®Google Scholar
• Brier ME, Gooding JR, Harrington JM, et al. Serum trace metal association with response to erythropoiesis stimulating agents in incident and prevalent hemodialysis patients. Sci Rep. 2020;10(1):20202.
   PubMed Web of Science ®Google Scholar
• Zhu S, Zhang F, Shen A-W, et al. Metabolomics evaluation of patients with stage 5 chronic kidney disease before dialysis, maintenance hemodialysis, and peritoneal dialysis. Front Physiol. 2020;11:630646.
   PubMed Web of Science ®Google Scholar
• Hunter E, Percival B, Ahmad Z, et al. NMR-based metabolomics associated with chronic kidney disease in humans and animals: a one health perspective. Mol Cell Biochem. 2021;476(11):4133–4137.
   PubMed Web of Science ®Google Scholar
• Wang Y-C, Chiu C-H, Lin C-L, et al. Scrub typhus and depression: a nationwide cohort analysis. J Transl Med. 2018; 16(1):333.
   PubMedGoogle Scholar
• Riggs DW, Pearce R, Pfeffer CA, et al. Transnormativity in the psy disciplines: constructing pathology in the diagnostic and statistical manual of mental disorders and standards of care. Am Psychol. 2019;74(8):912–924.
   PubMed Web of Science ®Google Scholar
• Condon MD, Platt NJ, Zhang Y-F, et al. Plasticity in striatal dopamine release is governed by release-independent depression and the dopamine transporter. Nat Commun. 2019;10(1):4263.
   PubMedGoogle Scholar
• Gorinski N, Bijata M, Prasad S, et al. Attenuated palmitoylation of serotonin receptor 5-HT1A affects receptor function and contributes to depression-like behaviors. Nat Commun. 2019;10(1):3924.
   PubMedGoogle Scholar
• Herman FJ, Simkovic S, Pasinetti GM. Neuroimmune nexus of depression and dementia: Shared mechanisms and therapeutic targets. Br J Pharmacol. 2019;176(18):3558–3584.
   PubMed Web of Science ®Google Scholar
• Su J-A, Chang C-C, Wang H-M, et al. Antidepressant treatment and mortality risk in patients with dementia and depression: a nationwide population cohort study in Taiwan. Ther Adv Chronic Dis. 2019;10:2040622319853719.
   Web of Science ®Google Scholar
• Alshogran OY, Khalil AA, Oweis AO, et al. Association of brain-derived neurotrophic factor and interleukin-6 serum levels with depressive and anxiety symptoms in hemodialysis patients. Gen Hosp Psychiatry. 2018;53:25–31.
   PubMed Web of Science ®Google Scholar
• Navarrete M, Cuartero MI, Palenzuela R, et al. Astrocytic p38alpha MAPK drives NMDA receptor-dependent long-term depression and modulates long-term memory. Nat Commun. 2019;10(1):2968.
   PubMedGoogle Scholar
• Holmes SE, Scheinost D, Finnema SJ, et al. Lower synaptic density is associated with depression severity and network alterations. Nat Commun. 2019;10(1):1529.
   PubMed Web of Science ®Google Scholar
• Howard DM, Adams MJ, Shirali M, 23andMe Research Team, et al. Genome-wide association study of depression phenotypes in UK biobank identifies variants in excitatory synaptic pathways. Nat Commun. 2018;9(1):1470.
   PubMedGoogle Scholar
• Wang YN, Ma SX, Chen YY, et al. Chronic kidney disease: biomarker diagnosis to therapeutic targets. Clin Chim Acta. 2019;499:54–63.
   PubMed Web of Science ®Google Scholar
• Zhang Z-H, Mao J-R, Chen H, et al. Removal of uremic retention products by hemodialysis is coupled with indiscriminate loss of vital metabolites. Clin Biochem. 2017;50(18):1078–1086.
   PubMed Web of Science ®Google Scholar
• Hu J-R, Grams ME, Coresh J, et al. Serum metabolites and cardiac death in patients on hemodialysis. Clin J Am Soc Nephrol. 2019;14(5):747–749.
   PubMed Web of Science ®Google Scholar
• Zhao YY. Metabolomics in chronic kidney disease. Clin Chim Acta. 2013;422:59–69.
   PubMed Web of Science ®Google Scholar
• Zhao YY, Lin RC. Metabolomics in nephrotoxicity. Adv Clin Chem. 2014;65:69–89.
   PubMed Web of Science ®Google Scholar
• Gladine C, Ostermann AI, Newman JW, et al. MS-based targeted metabolomics of eicosanoids and other oxylipins: analytical and inter-individual variabilities. Free Radic Biol Med. 2019; 144:72–89.
   PubMed Web of Science ®Google Scholar
• Zhao YY, Lin RC. UPLC-MS(E) application in disease biomarker discovery: the discoveries in proteomics to metabolomics. Chem Biol Interact. 2014;215:7–16.
   PubMed Web of Science ®Google Scholar
• Martinez-Sena T, Luongo G, Sanjuan-Herraez D, et al. Monitoring of system conditioning after blank injections in untargeted UPLC-MS metabolomic analysis. Sci Rep. 2019;9(1) :9822.
   PubMedGoogle Scholar
• Zhao Y-Y, Wu S-P, Liu S, et al. Ultra-performance liquid chromatography-mass spectrometry as a sensitive and powerful technology in lipidomic applications. Chem Biol Interact. 2014;220:181–192.
   PubMed Web of Science ®Google Scholar
• Zhao YY, Cheng XL, Vaziri ND, et al. UPLC-based metabonomic applications for discovering biomarkers of diseases in clinical chemistry. Clin Biochem. 2014;47(15):16–26.
   PubMed Web of Science ®Google Scholar
• Hocher B, Adamski J. Metabolomics for clinical use and research in chronic kidney disease. Nat Rev Nephrol. 2017;13(5):269–284.
   PubMed Web of Science ®Google Scholar
• Schultheiss U, Sekula P. The promise of metabolomics in decelerating CKD progression in children. Clin J Am Soc Nephrol. 2021;16(8):1152–1154.
   PubMed Web of Science ®Google Scholar
• Zhou X, Liu L, Lan X, et al. Polyunsaturated fatty acids metabolism, purine metabolism and inosine as potential independent diagnostic biomarkers for major depressive disorder in children and adolescents. Mol Psychiatry. 2019;24(10):1478–1488.
   PubMed Web of Science ®Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56–62.
   PubMed Web of Science ®Google Scholar
• Wishart DS, Knox C, Guo AC, et al. HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res. 2009; 37(Database):D603–D610.
   PubMedGoogle Scholar
• Wang TJ, Larson MG, Vasan RS, et al. Metabolite profiles and the risk of developing diabetes. Nat Med. 2011; 17(4):448–453.
   PubMed Web of Science ®Google Scholar
• Westerhuis JA, van Velzen EJJ, Hoefsloot HCJ, et al. Multivariate paired data analysis: multilevel PLSDA versus OPLSDA. Metabolomics. 2010;6(1):119–128.
   PubMed Web of Science ®Google Scholar
• Molle T, Moreau Y, Clemancey M, et al. Redox behavior of the S-Adenosylmethionine (SAM)-binding Fe-S cluster in methylthiotransferase RimO, toward understanding dual SAM activity. Biochemistry. 2016;55(41):5798–5808.
   PubMed Web of Science ®Google Scholar
• Chen D-Q, Cao G, Chen H, et al. Identification of serum metabolites associating with chronic kidney disease progression and anti-fibrotic effect of 5-methoxytryptophan. Nat Commun. 2019;10(1):1476.
   PubMedGoogle Scholar
• Chen H, Cao G, Chen DQ, et al. Metabolomics insights into activated redox signaling and lipid metabolism dysfunction in chronic kidney disease progression. Redox Biol. 2016;10:168–178.
   PubMed Web of Science ®Google Scholar
• Zhao YY, Cheng XL, Wei F, et al. Intrarenal metabolomic investigation of chronic kidney disease and its TGF-β1 mechanism in induced-adenine rats using UPLC Q-TOF/HSMS/MS(E). J Proteome Res. 2013;12(2):692–2703.
   PubMed Web of Science ®Google Scholar
• Duranton F, Lundin U, Gayrard N, et al. Plasma and urinary amino acid metabolomic profiling in patients with different levels of kidney function. CJASN. 2014;9(1):37–45.
   PubMed Web of Science ®Google Scholar
• Pena MJ, Lambers Heerspink HJ, Hellemons ME, et al. Urine and plasma metabolites predict the development of diabetic nephropathy in individuals with type 2 diabetes mellitus. Diabet Med. 2014;31(9):1138–1147.
   PubMed Web of Science ®Google Scholar
• Feng YL, Cao G, Chen DQ, et al. Microbiome-metabolomics reveals gut microbiota associated with glycine-conjugated metabolites and polyamine metabolism in chronic kidney disease. Cell Mol Life Sci. 2019;76(24):4961–4978.
   PubMed Web of Science ®Google Scholar
• Chen L, Chen DQ, Liu JR, et al. Unilateral ureteral obstruction causes gut microbial dysbiosis and metabolome disorders contributing to tubulointerstitial fibrosis. Exp Mol Med. 2019;51(3):1–18.
   Web of Science ®Google Scholar
• Chen D-Q, Cao G, Chen H, et al. Gene and protein expressions and metabolomics exhibit activated redox signaling and wnt/β-catenin pathway are associated with metabolite dysfunction in patients with chronic kidney disease. Redox Biol. 2017;12:505–521.
   PubMed Web of Science ®Google Scholar
• Chen D-Q, Chen H, Chen L, et al. The link between phenotype and fatty acid metabolism in advanced chronic kidney disease. Nephrol Dial Transplant. 2017;32(7):1154–1166.
   PubMed Web of Science ®Google Scholar
• Benson JM, Shepherd DM. Dietary ligands of the aryl hydrocarbon receptor induce anti-Inflammatory and immunoregulatory effects on murine dendritic cells. Toxicol Sci. 2011;124(2):327–338.
   PubMed Web of Science ®Google Scholar
• Goldstein LE, Leopold MC, Huang X, et al. 3-Hydroxykynurenine and 3-hydroxyanthranilic acid generate hydrogen peroxide and promote alpha-crystallin cross-linking by metal ion reduction. Biochemistry. 2000;39(24):7266–7275.
   PubMed Web of Science ®Google Scholar
• Feng YL, Chen H, Chen DQ, et al. Activated NF-κB/Nrf2 and wnt/β-catenin pathways are associated with lipid metabolism in CKD patients with microalbuminuria and macroalbuminuria. Biochim Biophys Acta Mol Basis Dis. 2019;1865(9):2317–2332.
   PubMed Web of Science ®Google Scholar
• Zhao YY, Wang HL, Cheng XL, et al. Metabolomics analysis reveals the association between lipid abnormalities and oxidative stress, inflammation, fibrosis, and Nrf2 dysfunction in aristolochic acid-induced nephropathy. Sci Rep. 2015; 5:12936.
   PubMed Web of Science ®Google Scholar
• Eick SM, Meeker JD, Brown P, et al. Associations between socioeconomic status, psychosocial stress, and urinary levels of 8-iso-prostaglandin-F2α during pregnancy in Puerto Rico. Free Radic Biol Med. 2019;143:95–100.
   PubMed Web of Science ®Google Scholar
• Song J, Ma W, Gu X, et al. Metabolomic signatures and microbial community profiling of depressive rat model induced by adrenocorticotrophic hormone. J Transl Med. 2019;17(1):224.
   PubMedGoogle Scholar
• Wang J, Jiang C, Zhang K, et al. Melatonin receptor activation provides cerebral protection after traumatic brain injury by mitigating oxidative stress and inflammation via the Nrf2 signaling pathway. Free Radic Biol Med. 2019;131:345–355.
   PubMed Web of Science ®Google Scholar
• Balta S, Demırkol S, Kucuk U. The platelet lymphocyte ratio may be useful inflammatory indicator in clinical practice. Hemodial Int. 2013;17(4):668–669.
   PubMed Web of Science ®Google Scholar
• Turkmen K, Guney I, Yerlikaya FH, et al. The relationship between neutrophil-to-lymphocyte ratio and inflammation in end-stage renal disease patients. Renal Failure. 2012;34(2):155–159.
   PubMed Web of Science ®Google Scholar
• Zhang Z-H, Li M-H, Liu D, et al. Rhubarb protect against tubulointerstitial fibrosis by inhibiting TGF-β/smad pathway and improving abnormal metabolome in chronic kidney disease. Front Pharmacol. 2018;9:1029.
   PubMed Web of Science ®Google Scholar
• Tsai G, Coyle JT. N-acetylaspartate in neuropsychiatric disorders. Prog Neurobiol. 1995;46(5):531–540.
   PubMed Web of Science ®Google Scholar
• Coppen A, Shaw DM, Malleson A, et al. Tryptamine metabolism in depression. Br J Psychiatry. 1965;111(479):993–998.
   PubMedGoogle Scholar
• González-Ramírez EJ, Goñi FM, Alonso A. Mixing brain cerebrosides with brain ceramides, cholesterol and phospholipids. Sci Rep. 2019;9(1) :13326.
   PubMedGoogle Scholar
• Horrobin DF. Phospholipid metabolism and depression: the possible roles of phospholipase A2 and coenzyme A-independent transacylase. Hum Psychopharmacol. 2001; 16(1):45–52.
   PubMed Web of Science ®Google Scholar
• Chen H, Miao H, Feng YL, et al. Metabolomics in dyslipidemia. Adv Clin Chem. 2014;66:101–119.
   PubMed Web of Science ®Google Scholar
• Zhao YY, Vaziri ND, Lin RC. Lipidomics: new insight into kidney disease. Adv Clin Chem. 2015;68:153–175.
   PubMed Web of Science ®Google Scholar
• Zhang Z-H, Chen H, Vaziri ND, et al. Metabolomic signatures of chronic kidney disease of diverse etiologies in the rats and humans. J Proteome Res. 2016;15(10):3802–3812.
   PubMed Web of Science ®Google Scholar
• Zhao YY, Cheng XL, Lin RC, et al. Lipidomics applications for disease biomarker discovery in mammal models. Biomark Med. 2015;9(2):153–168.
   PubMed Web of Science ®Google Scholar
• Chen H, Chen L, Liu D, et al. Combined clinical phenotype and lipidomic analysis reveals the impact of chronic kidney disease on lipid metabolism. J Proteome Res. 2017;16(4):1566–1578.
   PubMed Web of Science ®Google Scholar
• Zhang Z-H, Vaziri ND, Wei F, et al. An integrated lipidomics and metabolomics reveal nephroprotective effect and biochemical mechanism of Rheum officinale in chronic renal failure. Sci Rep. 2016;6:22151.
   PubMed Web of Science ®Google Scholar
• Dou F, Miao H, Wang J-W, et al. An integrated lipidomics and phenotype study reveals protective effect and biochemical mechanism of traditionally used alisma Orientale juzepzuk in chronic renal disease. Front Pharmacol. 2018;9:53.
   PubMed Web of Science ®Google Scholar